Skip to main content

Table 1 Patients' characteristics

From: Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies

Patient Tumor (histotype) FIGO Stage Tumor grade Number of previous chemotherapy cycles
UPN #1 Endometrial carcinoma (endometrioid) Ic G3 4
UPN #2 Endometrial carcinoma (serous) IV G3 5
UPN #3 Ovarian carcinoma (serous) IIIb G3 4
UPN #4 Cervical carcinoma (squamous) Ib2 G2 2
UPN #5 Ovarian carcinoma (serous) IIIc G3 3
UPN #6 Endometrial carcinoma (mixed) Ic G2 1
UPN #7 Ovarian carcinoma (serous) Ic G3 4
UPN #8 Ovarian carcinoma IIIc G3 4
UPN #9 Ovarian carcinoma (serous) IIIc G3 4
UPN #10 Endometrial carcinoma (endometrioid) Ic G3 4
UPN #11 Ovarian carcinoma (endometrioid) IIIc G3 3
UPN #12 Ovarian carcinoma (endometrioid) IIIb G2 4
  1. The demographic characteristics of the 12 patients enrolled in this study are shown. Patients had not received any chemotherapy in the 21 days preceding the commencement of the carboplatin/paclitaxel regimen (see Materials and Methods for further details). FIGO = International Federation of Gynecology and Obstetrics. UPN = Unique Patient Number.